Balaxi Pharmaceuticals Ltd (BALAXI) share price, results

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	54.72	60.79	59.83	65.62	77.38	73.29	76.27	70.74	56.18	72.54	70.71	80.68
Expenses	43.96	47.14	46.36	55.53	66.79	69.30	63.72	66.58	55.02	69.45	70.59	76.02
Operating Profit	10.76	13.65	13.47	10.09	10.59	3.99	12.55	4.16	1.16	3.09	0.12	4.66
OPM %	19.66%	22.45%	22.51%	15.38%	13.69%	5.44%	16.45%	5.88%	2.06%	4.26%	0.17%	5.78%
Other Income	5.93	1.51	-0.70	-1.85	-4.11	3.94	-1.69	-1.78	1.59	0.10	2.92	-0.99
Interest	0.37	0.41	0.61	0.37	0.45	1.38	0.74	1.01	0.89	1.02	0.99	0.73
Depreciation	0.66	0.48	0.67	0.49	0.46	0.48	0.46	0.46	0.48	0.56	0.65	0.85
Profit before tax	15.66	14.27	11.49	7.38	5.57	6.07	9.66	0.91	1.38	1.61	1.40	2.09
Tax %	7.92%	4.77%	4.87%	12.06%	17.41%	11.70%	10.56%	67.03%	84.06%	80.75%	56.43%	38.28%
Net Profit	14.43	13.59	10.93	6.48	4.59	5.36	8.64	0.29	0.21	0.31	0.61	1.30
EPS in Rs	2.82	2.65	2.01	1.17	0.83	0.97	1.57	0.05	0.04	0.06	0.11	0.24

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	14	46	231	279	336	241	293	270	280
Expenses	12	37	189	229	279	197	254	261	271
Operating Profit	2	8	43	51	57	45	38	10	9
OPM %	11%	18%	18%	18%	17%	18%	13%	3.5%	3.2%
Other Income	1	1	2	5	3	-38	-4	3	4
Interest	0	0	0	1	1	3	4	5	4
Depreciation	0	0	0	1	2	2	2	2	3
Profit before tax	2	9	44	55	57	2	29	5	6
Tax %	19%	31%	14%	13%	19%	219%	13%	73%
Net Profit	2	6	38	48	46	-2	25	1	2
EPS in Rs	1.30	1.22	7.63	9.53	9.03	-0.44	4.54	0.26	0.45
Dividend Payout %	0%	0%	0%	1%	0%	0%	0%	0%

	10 Years	5 Years	3 Years	TTM	1 Year	Last Year
Compounded Sales Growth	%	3%	-7%	-6%
Compounded Profit Growth	%	-48%	-69%	-87%
Stock Price CAGR	21%	-27%	-36%		-47%
Return on Equity	%	8%	-4%			1%

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	3	10	10	10	10	11	11	11
Reserves	0	18	55	103	173	190	221	238
Borrowings	0	0	4	4	13	19	53	58
Other Liabilities	3	8	31	60	43	38	25	30
Total Liabilities	6	36	100	176	240	258	310	337
Fixed Assets	0	0	2	29	41	41	41	82
CWIP	0	0	0	1	3	2	22	0
Investments	0	0	3	0	0	0	0	0
Other Assets	6	36	94	147	195	215	247	255
Total Assets	6	36	100	176	240	258	310	337

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-2	-14	0	34	6	5	-35	-4
Cash from Investing Activity	-0	-0	-6	-28	-11	-1	-22	-21
Cash from Financing Activity	0	18	4	-0	26	30	34	0
Net Cash Flow	-2	4	-2	6	21	34	-23	-25
Free Cash Flow	-2	-14	-3	7	-9	4	-57	-25
CFO/OP	-97%	-161%	6%	78%	32%	26%	-83%	2%

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	147	238	121	36	57	84	138	184
Inventory Days		9	29	184	189	233	173	202
Days Payable		64	53	92	62	82	36	51
Cash Conversion Cycle	147	183	97	129	184	235	275	335
Working Capital Days	82	181	91	92	122	142	186	236
ROCE %		57%	93%	60%	37%	21%	13%	3%

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	71.22%	71.22%	66.86%	65.99%	65.99%	65.99%	65.99%	65.99%	65.99%	65.99%	65.99%	65.99%
FIIs	18.57%	18.57%	17.21%	16.88%	16.48%	16.48%	16.02%	8.87%	3.50%	1.74%	0.00%	0.00%
DIIs	0.03%	0.03%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	2.56%	2.56%
Public	10.18%	10.18%	15.91%	17.11%	17.50%	17.50%	17.96%	25.12%	30.49%	32.24%	31.45%	31.45%
No. of Shareholders	5,047	5,045	5,206	6,586	7,863	8,529	9,994	13,737	14,620	15,085	15,176	14,682

Fundamentals

Market Cap₹ 127 Cr.

Current Price₹ 23.0

Stock P/E52.3

Book Value₹ 45.1

ROCE3.47 %

ROE0.59 %

Dividend Yield0.00 %

Face Value₹ 2.00

Compounded Sales Growth (TTM)-6%

Compounded Profit Growth (TTM)-87%

Consolidated figures.

Valuation

Market capRs 122 Cr

Enterprise valueRs 79 Cr

P/E (TTM)50.09x

Price to book0.60x

Price to sales0.43x

EV / EBITDA6.23x

EV / EBIT7.80x

EV / sales0.28x

Price to cash flow25.00x

Earnings yield2.00%

P/E, 3-year average1.91x

P/B, 3-year average1.30x

P/E, 5-year average2.25x

P/B, 5-year average1.21x

Profitability

Operating margin (excl. other income)18.49%

Operating margin (incl. other income)2.85%

EBITDA margin4.52%

Pre-tax margin2.31%

Net profit margin0.87%

Net margin, latest quarter1.61%

ROE-1.24%

ROCE2.29%

ROA-0.96%

ROE, 3-year average27.77%

ROCE, 3-year average33.06%

ROA, 3-year average18.55%

ROE, 5-year average40.92%

ROCE, 5-year average49.65%

ROA, 5-year average28.17%

ROIC (approx.)-7.59%

Tax rate218.91%

Other income / net worth-18.74%

Growth

Sales growth (latest year)-28.28%

Profit growth (latest year)-105.20%

Sales CAGR, 3 years1.42%

Sales CAGR, 5 years77.75%

Sales growth QoQ14.10%

Profit growth QoQ113.11%

Sales growth YoY (latest quarter)14.05%

Profit growth YoY (latest quarter)348.28%

Per share

EPS (TTM)Rs 0.45

EPS (latest year)Rs -0.44

EPS (latest quarter)Rs 0.24

EPS, 3-year averageRs 30.79

EPS, 5-year averageRs 27.32

Book value per shareRs 36.95

Sales per shareRs 51.41

Cash flow per shareRs 0.89

Free cash flow per shareRs -4.59

Dividend per share, 3-year averageRs 0.50

Dividend per share, 5-year averageRs 0.50

Dividends

Dividend payout, 3-year average1.05%

Dividend payout, 5-year average1.05%

Efficiency

Asset turnover0.93x

Fixed asset turnover5.90x

Inventory turnover1.57x

Inventory days233 days

Debtor days84 days

Debtors turnover4.33x

Creditor days51 days

Cash conversion cycle335 days

Working capital days236 days

Leverage

Total debtRs 19 Cr

Cash and bankRs 62 Cr

Net debtRs -43 Cr

Debt to equity0.10x

Net debt / EBITDA-3.39x

Interest coverage2.79x

Owners' fund to total sources77.94%

Debt to assets7.51%

Cash flow

Cash from Operating Activity (latest year)Rs 5 Cr

Cash from Investing Activity (latest year)Rs -1 Cr

Cash from Financing Activity (latest year)Rs 30 Cr

Net Cash Flow (latest year)Rs 34 Cr

Free cash flow (latest year)Rs -25 Cr

FCFE (approx.: FCF + change in debt)Rs -19 Cr

Cash from ops / profit, 5 years0.05x

Sales to cash flow49.55x

Statement figures

Net sales (TTM)Rs 280 Cr

Net sales (latest year)Rs 241 Cr

Sales (latest quarter)Rs 81 Cr

Operating profit excl. other income (latest year)Rs 45 Cr

Operating profit (latest quarter)Rs 5 Cr

Other income (TTM)Rs 4 Cr

EBITDA (TTM)Rs 13 Cr

PBDT (TTM)Rs 9 Cr

Profit before tax (TTM)Rs 6 Cr

Tax (latest year)Rs 4 Cr

Net profit (TTM)Rs 2 Cr

Net profit (latest year)Rs -2 Cr

Net profit (latest quarter)Rs 1 Cr

Depreciation (TTM)Rs 3 Cr

Depreciation (latest quarter)Rs 1 Cr

Interest (TTM)Rs 4 Cr

Cost of goods sold (latest year)Rs 129 Cr

Total expenditure (latest year)Rs 197 Cr

Total income (latest year)Rs 204 Cr

Share capitalRs 11 Cr

ReservesRs 190 Cr

Shareholders' fundsRs 201 Cr

Total assetsRs 258 Cr

Net blockRs 41 Cr

Capital work in progressRs 2 Cr

ReceivablesRs 56 Cr

InventoryRs 82 Cr

Other liabilitiesRs 38 Cr

Shares outstanding (crore)5.45

Ownership

Promoter holding65.99% (+0.00 in a year)

Computed by MarketFriction from the consolidated statements. Returns use average balances.

P/E 50.1 is at the 54th percentile of its own 5.4-year range (median 17.0, low 7.8, high 325.1).

P/B 0.60 is at the 3th percentile (median 7.43).

Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.

Period	BALAXI	Nifty 50	Difference
1 week	-1.7%	-2.8%	+1.1 pts
1 month	-1.9%	-6.8%	+4.9 pts
3 months	-5.6%	-7.6%	+2.0 pts
6 months	+42.6%	+0.4%	+42.2 pts
1 year	-49.1%	-9.9%	-39.2 pts
2 years	-80.0%	-13.6%	-66.5 pts
3 years	-75.0%	+14.2%	-89.2 pts
5 years	-80.5%	+27.9%	-108.4 pts

Red flags

F-score 3 of 8

explain	Weak cash conversion Cash from operations was 49% of net profit over the last 3 years
explain	Receivables outrunning sales Receivables grew 7% vs sales -28% in 2026
explain	Debt up, profit down Borrowings up 46% while net profit fell in 2026

Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026

Sales ₹81 Cr +14.1% vs Jun 2025. Net profit ₹1 Cr +348.3%.

Against our estimate for Jun 2026: sales +19.0%, profit +358.0% in line. Our estimate for Sep 2026: sales Rs 58 Cr, profit Rs 0 Cr (how).

Activity

Compare

Company	Mcap (Cr)	P/E	ROCE
Sun Pharmaceutical Industries Ltd	447,476	35.4	20.5 %
Divis Laboratories Ltd	250,363	84.0	22.0 %
Torrent Pharmaceuticals Ltd	186,152	83.4	15.2 %
Zydus Lifesciences Ltd	119,750	24.6	21.1 %
Cipla Ltd	111,430	31.1	15.5 %
Laurus Labs Ltd	106,928	97.8	17.8 %
Mankind Pharma Ltd	105,120	49.3	13.5 %
Dr Reddys Laboratories Ltd	104,494	32.4	13.0 %
Aurobindo Pharma Ltd	97,682	25.8	12.9 %
Lupin Ltd	93,840	15.8	29.9 %
Glenmark Pharmaceuticals Ltd	68,905	22.1	39.8 %
Alkem Laboratories Ltd	62,772	27.6	21.2 %
Biocon Ltd	61,439	84.5	3.61 %
Abbott India Ltd	57,949	35.9	44.8 %
Gland Pharma Ltd	49,333	43.1	15.1 %

No bulk or block deals on record.

Ex-date	Action	Factor
2024-05-30	Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share	0.2000
2022-07-01	Annual General Meeting/Dividend - Rs 0.50 Per Share
2017-09-21	Annual General Meeting
2016-09-22	Annual General Meeting

Date	Type	What it says
2026-09-07	Updates	RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended August 2026 ..
2026-08-31	General Updates	The receipt of WHO-GMP Certification for Companys Pharmaceutical Formulation Manufacturing Facility.
2026-08-24	Director change	Change in Director(s) of the company.
2026-08-24	Shareholder meeting	Voting Results.
2026-08-24	Shareholder meeting	Proceedings of the 83rd Annual General Meeting held on 24th August, 2026
2026-08-10	Corrigendum	Corrigendum to Notice of the 83rd Annual General Meeting.
2026-08-07	Updates	RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended July 2026".
2026-08-06	Investor Presentation	Investor Presentation
2026-08-05	Updates	Progress of the Companys First Pharmaceutical Formulation Plant at Jadcherla, Hyderabad .
2026-08-05	Board meeting outcome	Outcome of Board Meeting held on 05th August, 2026.
2026-08-05	Board meeting outcome	Balaxi Pharmaceuticals Limited has submitted to the Exchange, the financial results for the quarter ended 30th June, 2026.
2026-07-31	Updates	Balaxi Pharmaceuticals Limited has informed the Exchange regarding BRSR for FY 2025-26..
2026-07-31	Shareholder meeting	Notice of 83rd Annual General Meeting to be held on 24th August, 2026.
2026-07-14	Reply to Clarification- Fina	The Exchange had sought clarification from BALAXI PHARMACEUTICALS LIMITED for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI ...
2026-07-09	Updates	RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended June 2026 ..
2026-06-24	Clarification - Financial Re	The Exchange has sought clarification from BALAXI PHARMACEUTICALS LIMITED for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI ...
2026-06-06	Updates	RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended May 2026 ..
2026-05-29	Investor Presentation	Investor Presentation
2026-05-28	Updates	Update on the Company s First Pharmaceuticals Formulation Plant at Jadcherla, Hyderabad,
2026-05-28	Appointment	Re-appointment of Ms. Akshita Ostwal as Independent Director of the company w.e.f. September 05, 2026 subject to shareholders approval in e...
2026-05-28	Appointment	Re- appointment of M/s Siva Rama Krishna & Associates as Internal Auditor of the Company for FY 2026-27
2026-05-28	Board meeting outcome	Outcome of Board Meeting held on May 28, 2026.
2026-05-28	Board meeting outcome	BALAXI PHARMACEUTICALS LIMITED has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-05-12	Updates	RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended April 2026.
2026-04-14	Updates	RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended February 2026 and March 2026"..

Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.

No short selling reported to NSE in our files.

Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.

High low price variation greater than 150perc in previous 12 monthsScrip PE is greater than 50 (4 trailing quarters)

Quick answers

What is the market cap of Balaxi Pharmaceuticals Ltd?

Balaxi Pharmaceuticals Ltd (BALAXI) has a market capitalisation of Rs 127 Cr. at the 2026-10-01 close.

What is the P/E ratio of Balaxi Pharmaceuticals Ltd?

Balaxi Pharmaceuticals Ltd trades at a P/E of 52.3 on trailing twelve-month profit, at the 2026-10-01 close.

What were Balaxi Pharmaceuticals Ltd's latest quarterly results?

In the Jun 2026 quarter, Balaxi Pharmaceuticals Ltd sales was Rs 81 Cr (+14.1% vs Jun 2025) and net profit was Rs 1 Cr.

What is the 52-week high and low of Balaxi Pharmaceuticals Ltd?

The 52-week high is Rs 45.34 and the 52-week low is Rs 15.20.